Genmab-developed drug reaches first-quarter expectations in US
One of Genmab’s partners, US-based Seagen, has just reported figures for its first-quarter performance that include numbers on cervical cancer drug Tivdak, which Genmab developed.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Kesimpta sales exceed first-quarter expectations
For subscribers
Genmab appeals arbitration defeat against Janssen
For subscribers